HuidaGene Therapeutics

Focus: HuidaGene Therapeutics is a China-based gene therapy and gene editing company focused on developing platform technologies for delivery vectors and gene editing approaches. The company is early-stage with a portfolio of 8 clinical programs primarily in rare genetic and ophthalmologic diseases.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About HuidaGene Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow HuidaGene Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HG204

MECP2 Duplication Syndrome

N/A

Clinical Trials (1)

NCT06615206A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)

N/A

Help build intelligence for HuidaGene Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build gene therapy platforms at ground level with potential for significant upside as the field matures in Asia-Pacific markets
Diverse pipeline across high-unmet-need indications (DMD, retinal diseases, hearing loss) with multiple shots on goal
Early-stage company structure allows for cross-functional impact and rapid learning in cutting-edge modalities

Watch Out For

Zero active job openings signals minimal hiring, organizational restructuring, or extended hiring freeze
Entirely pre-clinical/early Phase 1 portfolio with no Phase 3 programs means 7-10+ years to potential first approval and zero near-term catalysts
Limited public financial data, publication record (0 publications), and funding transparency create uncertainty about company stability and scientific credibility

Generated by Claude from HuidaGene Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

HG202

Neovascular Age-Related Macular Degeneration (nAMD)

Phase 1

Clinical Trials (1)

NCT06623279Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial

Phase 1

HG005

Stargardt Disease Type 1 (STGD1)

Phase 1

Clinical Trials (1)

NCT07063251An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease

Phase 1

HG302

Duchenne Muscular Dystrophin (DMD)

Phase 1

Clinical Trials (1)

NCT06594094An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)

Phase 1

HG004

Leber Congenital Amaurosis

Phase 1

Clinical Trials (1)

NCT06088992Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)

Phase 1

HG202

Neovascular Age-related Macular Degeneration(nAMD)

Phase 1

Clinical Trials (1)

NCT06031727CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Phase 1

HG205

Congenital Hearing Loss

Phase 1

Clinical Trials (1)

NCT06025032a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND)

Phase 1

HG004

Leber Congenital Amaurosis

Phase 1/2

Clinical Trials (1)

NCT05906953Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)